Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Pyramid Biosciences

Request full access

Dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family

Waltham, United StatesFounded 2015Biotech & Life Sciences

About Pyramid Biosciences

Pyramid Biosciences, established in 2015, is a clinical-stage biotechnology firm focused on developing precision medicines for cancer and other molecularly-defined diseases. The company was co-founded by Jordan Leef and Dr. Kollol Pal. Dr. Pal, a serial entrepreneur with extensive experience in the pharmaceutical and biotech industries, has a history of founding and leading successful early-stage companies, including Mnemosyne Pharmaceuticals and Corbus Pharmaceuticals. Mr. Leef brought experience from the financial sector, specifically in private equity and biotechnology equity research, with previous roles at Pharos Capital Group and C.E. Unterberg, Towbin.

The company's business model centers on identifying and advancing therapies that target clinically validated biological mechanisms to address significant unmet medical needs. Pyramid Biosciences generates value through the clinical development and potential commercialization of its therapeutic pipeline, which has been supported by over $60 million in financing from investors such as Adage Capital Management, Oracle Investment Management, and J.W. Childs Associates L.P. This funding has been crucial for accelerating the company's clinical programs.

The core of Pyramid's operations is its pipeline of drug candidates targeting the tropomyosin receptor kinase (TRK) family of receptors. One of its leading programs is PBI-200, an orally-active, central nervous system (CNS) penetrant TRK inhibitor. This drug is engineered to treat a variety of genetically defined cancers, including primary and metastatic brain tumors, and is designed to overcome resistance seen in other TRK inhibitor therapies. Another significant asset is PBI-100, a topical TRK inhibitor being developed for dermatological conditions like psoriasis and atopic dermatitis due to its anti-itch, anti-inflammatory, and antiproliferative properties. In April 2023, the company expanded its oncology portfolio by licensing GQ1010, an antibody-drug conjugate (ADC) targeting TROP2, from GeneQuantum Healthcare for development and commercialization outside of Greater China. The company was acquired by Biohaven in January 2024.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2015
Headquarters
Waltham, United States
Employees
10
Open positions
None listed
Dealroom signal
56.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Oct 2021 $34M $134M Adage Capital · Prospect Hill Growth Partners · Averill Master Fund · Oracle Investment Management —
EARLY VCOther financing Sep 2020 $28M $112M Adage Capital · Prospect Hill Growth Partners —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Pyramid Biosciences website traffic

Latest recorded traffic for Pyramid Biosciences is 310 monthly website visits, up 0% over the last three months. Pyramid Biosciences's team grew 0% over the past year.

Latest monthly visits310 3-month web change0% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Pyramid Biosciences in the Waltham ecosystem

Live from Dealroom

The Pyramid Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Boston Harbor Angels
  • Alpine Meridian Ventures

Series A4 investors entered at this stage

  • Adage Capital
  • Prospect Hill Growth Partners
  • Oracle Investment Management
  • Averill Master Fund
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Waltham HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Pyramid Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pyramid Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.